Celldex Therapeutics, Inc.
CLDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$157,863 | -$141,429 | -$112,325 | -$70,511 |
| Dep. & Amort. | $3,177 | $3,008 | $1,400 | $3,068 |
| Deferred Tax | $0 | $0 | $0 | -$227 |
| Stock-Based Comp. | $34,242 | $23,890 | $0 | $8,953 |
| Change in WC | -$21,601 | $13,462 | -$3,898 | -$1,054 |
| Other Non-Cash | -$15,733 | -$6,222 | $11,091 | -$1,138 |
| Operating Cash Flow | -$157,778 | -$107,291 | -$103,732 | -$60,909 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$1,919 | -$1,818 | -$1,828 | -$1,249 |
| Net Acquisitions | $0 | $0 | $69 | $27 |
| Inv. Purchases | -$789,924 | -$424,561 | -$188,965 | -$389,881 |
| Inv. Sales/Matur. | $501,714 | $320,597 | $280,666 | $174,947 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$290,129 | -$105,782 | $89,942 | -$216,156 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $432,298 | $216,222 | $4,076 | $269,893 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $9,151 | $2,236 | $0 | $2,479 |
| Financing Cash Flow | $441,449 | $218,458 | $4,076 | $272,372 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$6,458 | $5,385 | -$9,714 | -$4,693 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $34,814 | $29,429 | $39,143 | $43,836 |
| End Cash | $28,356 | $34,814 | $29,429 | $39,143 |
| Free Cash Flow | -$159,697 | -$109,109 | -$105,560 | -$62,158 |